Impact of Type 2 Diabetes Mellitus on Liver Fibrosis and Hepatic Steatosis in Patients with Primary Biliary Cholangitis: A Longitudinal Study
Digestive Diseases and Sciences · 2026
DOI: 10.1007/s10620-026-09672-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Elizabeth E Williams und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, 702 Rotary Circle Suite 225, Indianapolis…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver Cirrhosis, Biliary, Fatty Liver, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: The prevalence of type 2 diabetes mellitus (T2DM) and its associated hepatic steatosis has surged with the obesity epidemic. The influence of T2DM on the natural history of primary biliary cholangitis (PBC) remains poorly characterized. AIMS: This study aims to assess the prevalence of T2DM in a PBC cohort and evaluate its impact on hepatic steatosis, liver fibrosis, and clinical outcomes. METHODS: A retrospective analysis was performed. The presence of hepatic steatosis was defined by a controlled attenuation parameter (CAP) ≥ 285 dB/m, and clinically significant liver fibrosis was defined by a liver stiffness measurement (LSM) ≥ 8.5 kPa assessed using vibration-controlled transient elastography (VCTE). The cohort was further stratified into four subgroups: PBC with T2DM (PBC/T2DM), PBC without T2DM (PBC/non-T2DM), PBC with hepatic steatosis (PBC/steatosis), and PBC without hepatic steatosis (PBC/no steatosis). Group comparisons were performed using t-tests, chi-squared analyses, and Kaplan-Meier survival curves. RESULTS: 562 patients with PBC were identified. The prevalence of T2DM was 14.8%. 158 (28%) patients had VCTE measurements. The PBC/T2DM sub-cohort was more likely to have concomitant hepatic steatosis compared to PBC/non-T2DM (54% vs 28%, p-value 0.010). The prevalence of clinically significant fibrosis was similar between these two groups (69% vs 52%, p-value 0.097). All-cause mortality rates were similar between PBC/T2DM vs PBC/non-T2DM (p-value 0.960) and PBC/steatosis vs PBC/no steatosis (p-value 0.895). CONCLUSION: T2DM is a risk factor for the development of hepatic steatosis in patients with PBC; however, it does not increase the likelihood of clinically significant liver fibrosis or all-cause mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, 702 Rotary Circle Suite 225, Indianapolis, IN, 46202, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, 702 Rotary Circle Suite 225, Indianapolis, IN, 46202, USA. rvuppala@iu.edu.
Zitieren
APA
Williams, E. E., Lammert, C., & Vuppalanchi, R. (2026). Impact of Type 2 Diabetes Mellitus on Liver Fibrosis and Hepatic Steatosis in Patients with Primary Biliary Cholangitis: A Longitudinal Study. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-026-09672-5
Vancouver
Williams EE, Lammert C, Vuppalanchi R. Impact of Type 2 Diabetes Mellitus on Liver Fibrosis and Hepatic Steatosis in Patients with Primary Biliary Cholangitis: A Longitudinal Study. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-026-09672-5
BibTeX
@article{Williams2026,
author = {Williams, Elizabeth E and Lammert, Craig and Vuppalanchi, Raj},
title = {Impact of Type 2 Diabetes Mellitus on Liver Fibrosis and Hepatic Steatosis in Patients with Primary Biliary Cholangitis: A Longitudinal Study},
journal = {Digestive Diseases and Sciences},
year = {2026},
doi = {10.1007/s10620-026-09672-5}
}
EUVIMED